Retinopathy of prematurity
Conditions
Brief summary
Survival without threshold ROP (stage 3 or more severe ROP(including aggressive posterior ROP))
Detailed description
Time to adverse ophthalmological outcome in days, Ophthalmological outcome categorized as survival without adverse ophthalmological outcome, or death, Survival until 48 weeks PMA without ROP, treated with ablative laser surgery or intravitreal VEGF antagonists, Death until discharge, Death until 48 weeks PMA, ROP retreatment: Need for repeated ROP therapy in infants treated with anti-VEGF-antagonists until 70 ( 2 weeks) PMA
Interventions
DRUGComposition
DRUGidentical to the IMP
DRUGPROPRANOLOL HYDROCHLORIDE
Sponsors
Universitaetsklinikum Tuebingen AöR, Universität Zürich - Klinik für Neonatologie
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival without threshold ROP (stage 3 or more severe ROP(including aggressive posterior ROP)) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to adverse ophthalmological outcome in days, Ophthalmological outcome categorized as survival without adverse ophthalmological outcome, or death, Survival until 48 weeks PMA without ROP, treated with ablative laser surgery or intravitreal VEGF antagonists, Death until discharge, Death until 48 weeks PMA, ROP retreatment: Need for repeated ROP therapy in infants treated with anti-VEGF-antagonists until 70 ( 2 weeks) PMA | — |
Countries
Germany
Outcome results
None listed